To include your compound in the COVID-19 Resource Center, submit it here.

Tougher Tregs

How Casebia is using CRISPR to create stable Tregs for autoimmune diseases

Casebia Therapeutics is using gene editing to engineer autologous Tregs with more durable immunosuppressive activity than unmodified Tregs, and plans to use the cells to treat a variety of autoimmune diseases.

Casebia is a JV formed by CRISPR Therapeutics AG and Bayer AG with IP from the former and funding and disease-relevant experience from the latter. The JV is applying the biotech’s gene editing platform

Read the full 644 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE